Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems. Key products include the OLpur MDHDF filter series (sold in Europe), the OLpur H2H module (pending FDA approval), and the Dual Stage Ultrafilter (DSU) for water purification. The company operates as a smaller reporting company with facilities in New Jersey and Ireland.
Key Financial Metrics
| Metric | 2010 | 2009 |
|---|---|---|
| Product Revenue | $2,938,000 | $2,661,000 |
| Gross Margin | $1,122,000 (38.2%) | $917,000 (34.5%) |
| Net Loss | $(1,933,000) | $(2,026,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.93) | $(1.06) |
| Cash and Cash Equivalents (Year End) | $240,000 | $1,004,000 |
| Net Cash Used in Operating Activities | $(1,292,000) | $(2,612,000) |
| Short-Term Borrowings | $500,000 | $0 |
| Accumulated Deficit | $(91,908,000) | $(89,975,000) |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 10% to $2.94 million, driven by a $305,000 increase in DSU sales in the U.S. and a $220,000 increase in European MD filter sales (offset partially by foreign currency fluctuations).
- Cost of Goods Sold (COGS): COGS rose 4% to $1.82 million due to higher DSU sales volume, though costs related to the U.S. Naval Research contract decreased due to subcontractor usage.
- Operating Expenses: Selling, General, and Administrative (SG&A) expenses decreased 10% to $2.52 million, primarily due to reduced personnel and marketing costs. Research and Development (R&D) expenses increased 29% to $362,000.
- Liquidity: Cash reserves declined significantly from $1.0 million to $240,000. The company issued a $500,000 senior secured note in October 2010 to bridge liquidity gaps.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. The financial statements do not include adjustments that might result from this uncertainty.
Regulatory Status and Outlook
- FDA Approval: On June 30, 2010, the FDA issued a final decision letter stating it could not reach a "substantial equivalence" determination for the company's HDF system (OLpur H2H and MD220). The company is evaluating options, including filing a new 510(k) application, with a target submission in Q3 2011.
- European Market: The company continues to sell MD filters in Europe where it holds CE marking.
- Water Filtration: The DSU received FDA approval in July 2009 for use in hemodialysis water purification. The company is pursuing military contracts (Office of Naval Research) and commercial hospital markets.
Subsequent Events (Post-Year End)
- Capital Raise: In March 2011, the company completed a rights offering and private placement raising approximately $3.2 million in gross proceeds (net ~$2.3 million). Proceeds were used to repay the $500,000 Lambda Investors note.
- Reverse Stock Split: A 1-for-20 reverse stock split became effective on March 11, 2011, reducing outstanding shares from ~201 million to ~10.1 million.
Key Risks
- Customer Concentration: Two customers accounted for 79% of 2010 sales and 84% of accounts receivable.
- Supply Chain: The exclusive fiber supply agreement was terminated by the supplier in July 2010, though negotiations for a new agreement were ongoing.
- Competition: Intense competition from major dialysis providers (Fresenius, Gambro) who also own clinics.
Investor Verification Checklist
- Capital Adequacy: Verify the sufficiency of the $2.3 million net proceeds from the March 2011 offering to fund operations until profitability or further financing.
- FDA Timeline: Monitor the status of the new 510(k) application for the HDF system, as U.S. commercialization depends entirely on this approval.
- Customer Dependency: Assess the risk of losing the two major customers representing nearly 80% of revenue.
- Supply Agreement: Confirm the status of the new fiber supply agreement following the termination of the previous exclusive contract.
- Stock Structure: Note the 1-for-20 reverse stock split and the significant ownership concentration (Lambda Investors LLC owns ~71% of outstanding stock).